Open, Multicenter, Local, Non-Randomized, Non-Interventional Study in Patients With Chronic Hepatitis B Receiving Therapy With PEGASYS® (Peginterferon Alfa-2a 40kD) - PRO B
Phase of Trial: Phase IV
Latest Information Update: 05 Sep 2017
Price : $35 *
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms PRO B
- Sponsors Roche
- 30 Aug 2017 Status changed from active, no longer recruiting to completed.
- 16 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Apr 2016 Planned End Date changed from 1 May 2016 to 1 Jun 2018 as reported by ClinicalTrials.gov record.